※一部利用できない機能があります
| 1.
論文（リポジトリ） |
論文（リポジトリ）
|
Kinjo, Takeshi ; Toma, Hiromu ; Fujita, Jiro
|
||||||
| 2.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakamura, Hideta ; Ouchi, Gen ; Miyagi, Kazuya ; Higure, Yuuri ; Otsuki, Mariko ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Tateyama, Masao ; Kukita, Ichiro ; Fujita, Jiro
概要:
Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal
…
hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports to identify clinical characteristics of IPH in COVID-19 patients. The use of anticoagulants may increase the risk of lethal IPH among COVID-19 patients becsuse of scarce data on optimal dosage and adequate monitoring of anticoagulant effects. Rapid diagnosis and timely intervention are crucial to ensure good patient outcomes.
続きを見る
|
||||||
| 3.
図書 |
図書
|
Jiro Fujita editors
|
||||||
| 4.
論文（リポジトリ） |
論文（リポジトリ）
|
Furugen, Makoto ; Shibahara, Daisuke ; Kiyuna, Tomo ; Kami, Wakaki ; Miyagi, Kazuya ; Haranaga, Shusaku ; Kubota, Toru ; Matsumoto, Hirofumi ; Yoshimi, Naoki ; Fujita, Jiro
概要:
Pemetrexed has significant efficacy for some non-squamous non-small cell lung cancer cases, as demonstrated in the current case. For those patients, pemetrexed administration should be carefully considered.
|
||||||
| 5.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro
概要:
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release synd
…
rome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
論文 続きを見る |
||||||
| 6.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakamura, Hideta ; Tateyama, Masao ; Tasato, Daisuke ; Haranaga, Shusaku ; Higa, Futoshi ; Matsuzaki, Akiko ; Yoshimi, Naoki ; Fujita, Jiro
概要:
Asymptomatic pulmonary sarcoidosis can develop after starting antiretroviral therapy. The decision on whether to treat sarcoidosis with corticosteroids should be based on the disease severity.
|
||||||
| 7.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakamura, Hideta ; Kinjo, Takeshi ; Arakaki, Wakako ; Miyagi, Kazuya ; Tateyama, Masao ; Fujita, Jiro
概要:
論文
|
||||||
| 8.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakamura, Hideta ; Kinjo, Takeshi ; Arakaki, Wakako ; Miyagi, Kazuya ; Tateyama, Masao ; Fujita, Jiro
|
||||||
| 9.
論文（リポジトリ） |
論文（リポジトリ）
|
Yamauchi, Momoko ; Kinjo, Takeshi ; Parrott, Gretchen ; Miyagi, Kazuya ; Haranaga, Shusaku ; Nakayama, Yuko ; Chibana, Kenji ; Fujita, Kaori ; Nakamoto, Atsushi ; Higa, Futoshi ; Owan, Isoko ; Yonemoto, Koji ; Fujita, Jiro
概要:
Serum markers that differentiate between tuberculous and non-tuberculous pneumonia would be clinically useful. However,
…
few serum markers have been investigated for their association with either disease. In this study, serum levels of interferon gamma (IFN-γ), matrix metalloproteinases 1 and 9 (MMP-1 and MMP-9, respectively), and periostin were compared between 40 pulmonary tuberculosis (PTB) and 28 non-tuberculous pneumonia (non-PTB) patients. Diagnostic performance was assessed by analysis of receiver-operating characteristic (ROC) curves and classification trees. Serum IFN-γ and MMP-1 levels were significantly higher and serum MMP-9 levels significantly lower in PTB than in non- PTB patients (p < 0.001, p = 0.002, p < 0.001, respectively). No significant difference was observed in serum periostin levels between groups. ROC curve analysis could not determine the appropriate cut-off value with high sensitivity and specificity; therefore, a classification tree method was applied. This method identified patients with limited infiltration into three groups with statistical significance (p = 0.01), and those with MMP-1 levels < 0.01 ng/ mL and periostin levels ≥ 118.8 ng/mL included only non-PTB patients (95% confidence interval 0.0–41.0). Patients with extensive infiltration were also divided into three groups with statistical significance (p < 0.001), and those with MMP-9 levels < 3.009 ng/mL included only PTB patients (95% confidence interval 76.8–100.0). In conclusion, the novel classification tree developed using MMP-1, MMP-9, and periostin data distinguished PTB from non- PTB patients. Further studies are needed to validate our cut-off values and the overall clinical usefulness of these markers.
論文 続きを見る |
||||||
| 10.
論文（リポジトリ） |
論文（リポジトリ）
|
Hashioka, Hiroe ; Kami, Wakaki ; Miyazato, Kouya ; Miyagi, Kazuya ; Hokama, Akira ; Fujita, Jiro
概要:
論文
|
